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Background Sodium–glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure
hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients
in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals
with established heart failure (with or without diabetes) is unknown.
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Design
and methods
The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) is an international,
multicentre, parallel group, randomized, double-blind, study in patients with chronic heart failure, evaluating the effect
of dapagliflozin 10mg, compared with placebo, given once daily, in addition to standard care, on the primary composite
outcome of a worsening heart failure event (hospitalization or equivalent event, i.e. an urgent heart failure visit) or
cardiovascular death. Patients with and without diabetes are eligible and must have a left ventricular ejection fraction
≤ 40%, a moderately elevated N-terminal pro B-type natriuretic peptide level, and an estimated glomerular filtration
rate ≥ 30mL/min/1.73m2. The trial is event-driven, with a target of 844 primary outcomes. Secondary outcomes
include the composite of total heart failure hospitalizations (including repeat episodes), and cardiovascular death and
patient-reported outcomes. A total of 4744 patients have been randomized.
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Conclusions DAPA-HF will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy,
in a broad spectrum of patients with heart failure and reduced ejection fraction.
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Introduction
Although being one of the most common, disabling and deadly
complications of diabetes, heart failure has not been the focus
of cardiovascular outcome trials evaluating glucose-lowering
therapies.1,2 Despite this, evidence has accrued that different
diabetes medications have distinct effects on the risk of developing
heart failure.1,2 Specifically, thiazolidinediones and saxagliptin (and
possibly alogliptin) increase the risk of heart failure hospitalization,
whereas in three recent trials there were nominally statisti-
cally significant reductions in heart failure hospitalization with
sodium–glucose co-transporter 2 (SGLT2) inhibitors.3–9 In the
EMPA-REG OUTCOME trial, the relative risk reduction in heart
failure hospitalization among patients with type 2 diabetes treated
with empagliflozin was 35%,7 in the Canagliflozin Cardiovascular
Assessment Study Program (CANVAS), the reduction was 33%,8
and in the Dapagliflozin Effect on CardiovascuLAR Events trial
(DECLARE–TIMI 58) the reduction was 27%.9 These exciting
findings have raised many questions, including what type (or types)
of heart failure occurred in these patients (i.e. with reduced or
preserved ejection fraction), through which mechanism(s) SGLT2
inhibitors exert these salutary effects and whether they may even
be independent of glucose-lowering, and if they might extend
to patients without type 2 diabetes?3–12 Additional mechanisms
proposed include diuretic and haemodynamic actions, improved
myocardial metabolism, effects on cardiac ion channels and
others.3–12 The beneficial effects of SGLT2 inhibitors on kidney
function may also be relevant.3–12
An even bigger question is whether SGLT2 inhibitors might also
be of benefit in patients with established heart failure. Few patients
in EMPA-REG OUTCOME, CANVAS and DECLARE–TIMI 58
had a diagnosis of heart failure at baseline and the heart failure
phenotype of those that did has not been reported.7,8 Yet diabetes
and pre-diabetic dysglycaemia are extremely common in individuals
with heart failure, and heart failure patients with diabetes or
pre-diabetes are at especially high risk of cardiovascular death and
heart failure hospitalization.13,14 Consequently, a treatment that
both lowers glucose and improves heart failure outcomes is greatly
needed, particularly if not accompanied by weight gain and the risk
of hypoglycaemia, as is the case with some conventional therapies
(insulin and insulin secretagogues). Moreover, it is possible that the
favourable mechanisms of action of SGLT2 inhibitors might even
extend to heart failure patients without manifest dysglycaemia.3–12
To further explore these possibilities, we have designed a
prospective randomized, placebo-controlled trial examining the
effect of dapagliflozin on morbidity and mortality in patients
with heart failure with reduced ejection fraction (HFrEF) — the
Dapagliflozin And Prevention of Adverse-outcomes in Heart Fail-
ure trial (DAPA-HF).
Methods
DAPA-HF is an international, multicentre, parallel group, event-driven,
randomized, double-blind, trial in patients with chronic HFrEF, evalu-
ating the effect of dapagliflozin 10mg, compared with placebo, given
once daily, in addition to standard of care, on the risk of worsening ..
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.. heart failure and cardiovascular death. The trial is registered as Clini-
calTrials.gov Identifier: NCT03036124.
Study design and conduct
Patients
Men and women aged 18 years or older with a diagnosis of heart fail-
ure for at least 2months are eligible if they are in New York Heart
Association functional class II or above, have a left ventricular ejection
fraction documented to be ≤ 40% within the last 12months, are opti-
mally treated with pharmacological and device therapy for heart failure,
and willing to provide written informed consent. In addition, patients
must have a N-terminal pro B-type natriuretic peptide concentration
≥ 600 pg/mL or, if hospitalised for heart failure within the previous
12months, ≥ 400 pg/mL. Patients with atrial fibrillation or atrial flutter
must have a level ≥ 900 pg/mL, irrespective of history of heart failure
hospitalization. Full details are provided in the online supplementary
Appendix S1.
Key exclusion criteria include: recent treatment with or intolerance
of a SGLT2 inhibitor, type 1 diabetes mellitus, symptoms of hypotension
or systolic blood pressure < 95mmHg, recent worsening heart failure
or other cardiovascular events or procedures (or planned procedures),
estimated glomerular filtration rate (eGFR) < 30mL/min/1.73m2 (or
rapidly declining renal function) and other conditions likely to prevent
patient participation in the trial or greatly limit life expectancy. A full
list of exclusion criteria is provided in Table 1.
Treatment of heart failure
Patients should receive background standard drug and device
therapy for HFrEF, in accordance with recognized guidelines.
Guideline-recommended medications should be used at the tar-
get doses specified, unless contraindicated or not tolerated. Therapy
should have been individually optimized and stable for ≥ 4weeks (with
the exception of diuretics which can be dosed flexibly – see below).
Unless contraindicated or not tolerated, treatment should include:
(i) an angiotensin-converting enzyme (ACE) inhibitor, angiotensin
receptor blocker (ARB), or sacubitril/valsartan; (ii) a beta-blocker and,
if considered appropriate; (iii) a mineralocorticoid receptor antagonist
(MRA); further details are provided in the online supplementary
Appendix S1.
It is recognized that diuretic dosing may be titrated according to
symptoms, signs, weight and other information and may thus vary. Each
patient should, however, be treated with a diuretic regimen aimed at
achieving optimal fluid/volume status for that individual.
Treatment of diabetes
Patients with type 2 diabetes at randomization will continue to take
their glucose-lowering therapies but these can be adjusted at the
discretion of their diabetes health care provider. The dose of insulin
and/or sulfonylurea therapy may be reduced to minimize the risk
of hypoglycaemia, for example in patients with a baseline glycated
haemoglobin (HbA1c) < 7%.
Randomization
Once a patient fulfils the criteria for randomization, investigators use
the interactive voice or web response system (IxRS) to obtain treat-
ment assignment. Participants are assigned, double-blind, in balanced
blocks to ensure an approximate one-to-one ratio of dapagliflozin or
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Table 1 Exclusion criteria
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
1. Receiving therapy with an SGLT2 inhibitor within 8weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor
2. Type 1 diabetes mellitus
3. Symptomatic hypotension or systolic blood pressure < 95mmHg at two out of three measurements either at Visit 1 or Visit 2
4. Current acute decompensated HF or hospitalization due to decompensated HF < 4weeks prior to enrolment
5. Myocardial infarction, unstable angina, stroke or transient ischemic attack within 12weeks prior to enrolment
6. Coronary revascularization (percutaneous coronary intervention or coronary artery bypass grafting) or valvular repair/replacement within
12weeks prior to enrolment or planned to undergo any of these operations after randomization
7. Implantation of a CRT device within 12weeks prior to enrolment or intent to implant a CRT device
8. Previous cardiac transplantation or implantation of a ventricular assistance device or similar device, or implantation expected after
randomization
9. HF due to restrictive cardiomyopathy, active myocarditis, constrictive pericarditis, hypertrophic (obstructive) cardiomyopathy, or uncorrected
primary valvular disease
10. Symptomatic bradycardia or second or third-degree heart block without a pacemaker
11. Any condition outside the cardiovascular and renal disease area, such as but not limited to malignancy, with a life expectancy of < 2 years based
on investigator’s clinical judgement
12. Active malignancy requiring treatment at the time of Visit 1(with the exception of successfully treated basal cell or treated squamous cell
carcinoma)
13. Hepatic impairment (aspartate transaminase or alanine transaminase > 3× the ULN, or total bilirubin > 2× ULN at time of enrolment).
An isolated increase in bilirubin in patients with known Gilbert’s syndrome is not a reason for exclusion
14. Known blood-borne diseases representing a shipping/transportation biohazard
15. Severe (eGFR < 30mL/min/1.73m2 by CKD-EPI equation), unstable or rapidly progressing renal disease at the time of randomization
16. Women of child-bearing potential (i.e. those who are not chemically or surgically sterilised or who are not post-menopausal) who are not
willing to use a medically accepted method of contraception that is considered reliable in the judgement of the investigator, from the time of
signing the informed consent throughout the study and 4weeks thereafter, or women who have a positive pregnancy test at enrolment or
randomization, or women who are breast-feeding
17. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca personnel and/or personnel at the study site)
18. Previous randomization in the present study
19. Participation in another clinical study with an IP during the last month prior to enrolment
20. Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up, or
any conditions that, in the opinion of the investigator, may render the patient unable to complete the study
CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HF, heart failure; SGLT2,
sodium–glucose co-transporter 2; IP, investigational product; ULN, upper limit of normal.
matching placebo, in accordance with the sequestered, fixed random-
ization schedule.
Stratification and capping
Randomization will be stratified based on diagnosis of type 2 diabetes
[either an established diagnosis or a central laboratory HbA1c ≥ 6.5%
(48mmol/mol) at enrolment] and at least 30% of the patients enrolled
will have type 2 diabetes.
Study visits and follow-up
After provision of informed consent, Visit 1 starts a 14± 7 day enrol-
ment period during which the trial inclusion and exclusion criteria are
checked and baseline information is collected (including from clinical
examination and laboratory measurements). Visit 2 is the randomiza-
tion visit at which further assessments are conducted (Figure 1 and
online supplementary Table S1) and study drug is dispensed. Visit 3
takes place 14± 3 days and Visit 4 60± 7 days after randomization,
with a particular focus on assessment of heart failure and volume
status, adverse events, and checking blood chemistry (including renal ..
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. function and potassium). Further visits take place at 120± 7, 240± 14,
360±14 days and 4 monthly thereafter. The schedule of assessments
is shown in the online supplementary Table S1.
Study drug dose reduction/discontinuation
Study drug should be permanently discontinued if pregnancy or
diabetic ketoacidosis occur. Dose reduction (to dapagliflozin 5mg
daily or matching placebo) or temporary discontinuation may be
considered in cases of acute, unexpected, declines in eGFR (while
investigating other causes such as nephrotoxic drugs, urinary tract
infection, or obstruction). Similarly, in cases of volume depletion
and/or hypotension, alternative causes should be considered (e.g. gas-
trointestinal fluid loss, use of non-essential blood pressure-lowering
drugs) and the dose of concomitant diuretic therapy re-assessed
and reduced, if appropriate. Temporary interruption of study drug may
also be considered, prophylactically, in patients at potential risk of vol-
ume contraction/hypotension, such as patients with an acute medical
illness potentially causing volume depletion because of inadequate
fluid intake or fluid/blood losses (e.g. gastroenteritis, gastrointestinal
haemorrhage), or patients undergoing major surgery.
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• Informed consent
• Inclusion/exclusion
• Clinical assessment
• ECG
• NT proBNP
• Laboratory 
assessments
n~2250
n~2250
Placebo
Dapagliflozin10mg daily
≥844 Primary endpoints
Composite of: 
• CV death
• HF hospitalization
• Urgent HF visit
Day -14
Visit 6  etc.Visit 1 Visit 5Visit 4Visit 3Visit 2
Day 120Day 60Day 0 Day 14 Every 120 days
Enrolment Randomization
Figure 1 Trial design. CV, cardiovascular; ECG, electrocardiogram; HF, heart failure; NT-proBNP, N-terminal pro B-type natriuretic peptide.
The dose of evidence-based, life-saving, heart failure therapies
should not be reduced just to maintain treatment with study drug. If
possible, the dose of study drug should be increased again if the adverse
effect is resolved. Even if study drug is discontinued, investigators are
asked to ensure that scheduled study visits, follow-up procedures and
data collection continue according to the study protocol until study
closure.
Outcomes
Primary and other outcomes
The primary objective is to determine whether dapagliflozin is superior
to placebo, when added to standard care, in reducing the incidence
of a worsening heart failure episode (hospitalization or the equivalent,
i.e. an urgent heart failure visit) or cardiovascular death, analysed
as time-to-first event (Table 2).
The first of the secondary outcomes is the composite of heart
failure hospitalization or cardiovascular death. The additional sec-
ondary outcomes are: (i) total number of recurrent heart failure hos-
pitalizations and cardiovascular deaths; (ii) change from baseline to
8months in the total symptom score using the Kansas City Cardiomy-
opathy Questionnaire (KCCQ)15; patients will complete the KCCQ
and other patient-reported outcomes (PROs; Table 2) using a hand-
held electronic device; (iii) the incidence of a composite worsening
renal function outcome conisting of (a) ≥ 50% sustained decline in
eGFR, or ((b) end-stage renal disease (defined as sustained eGFR
< 15mL/min/1.73m2, chronic dialysis treatment or renal transplanta-
tion) or renal death; and (iv) death from any cause.
There are also a number of exploratory objectives (listed in Table 2),
including development of new diabetes and new atrial fibrillation, and
safety objectives, including documentation of adverse events of inter-
est comprising volume depletion, renal events, major hypoglycaemic
events, fractures, diabetic ketoacidosis, amputations, and events poten-
tially placing patients at risk of lower limb amputation.
Endpoint adjudication
An independent Cardiovascular Endpoint Committee (CEC), blinded
to treatment allocation, is adjudicating all deaths and non-fatal ..
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.. cardiovascular events submitted by investigators (or otherwise iden-
tified) as possible endpoints. The CEC will use a charter reflecting
the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical
Trials developed by the Standardized Data Collection for Cardiovas-
cular Trials Initiative.16 Episodes of possible ketoacidosis are also being
adjudicated.
Statistical considerations
Sample size assumptions and statistical analysis
Assuming a true hazard ratio (HR) of 0.80 for dapagliflozin vs. placebo,
and using a one-sided alpha of 2.5%, 844 primary endpoint events will
provide a statistical power of 90% for the test of the primary composite
endpoint.
With an annual event rate of 11% in the placebo treatment group,
approximately 4500 patients were estimated to provide the required
number of primary events, based on an anticipated recruitment period
of 18months and an average follow-up period of approximately
24months. The assumed placebo event rate of 11% is based on a
review of recently published clinical studies in the HFrEF popula-
tion, including the Prospective Comparison of ARNI with ACEI to
Determine Impact on Global Mortality and Morbidity in Heart Failure
(PARADIGM-HF) trial.17 The trial has a group sequential design with
one interim analysis (see below) by the Data Monitoring Committee
(DMC).
Methods for statistical analyses
We plan to use a closed testing procedure, including a pre-specified
hierarchical ordering of the primary and secondary endpoints (as listed
above). The Type I error will be controlled at a one-sided 0.02496
level for multiplicity across primary and secondary endpoints and in
consideration of planned interim analyses (as described above). Statis-
tical significance of the endpoints will be assessed in the order speci-
fied above. The testing procedure will continue down the hierarchy if
superiority for the preceding endpoint is demonstrated at a one-sided
0.02496 level and will stop if superiority is not achieved at a one-sided
0.02496 level. Exploratory endpoints will be tested at a one-sided 0.025
level without adjustment for multiplicity.
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Table 2 Primary, secondary and exploratory efficacy objectives and safety objectives
Outcome measure
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary objective
To determine whether dapagliflozin is superior to placebo, when added to
standard of care, in reducing the incidence of CV death or a HF event
(hospitalization for HF or equivalent HF event, i.e. an urgent HF visit)
Time to the first occurrence of any of the components of this
composite:
1. CV death
2. Hospitalization for HF
3. An urgent HF visit
Secondary objectives
• To compare the effect of dapagliflozin vs. placebo on CV death or
hospitalization for HF
Time to the first occurrence of either of the components of this
composite:
1. CV death
2. Hospitalization for HF
• To compare the effect of dapagliflozin vs. placebo on total number of
recurrent HF hospitalizations and CV death
Total number of (first and recurrent) HF hospitalizations and CV
deaths
• To compare the effect of treatment with dapagliflozin vs. placebo on
the KCCQ total symptom score for HF symptoms
Change from baseline measured at 8months in the total symptom
score of the KCCQ, a specific HF patient-reported outcome
questionnaire
• To determine if dapagliflozin compared with placebo reduces the
incidence of a composite endpoint of worsening renal function
Time to the first occurrence of any of the components of this
composite:
(1) ≥ 50% sustained decline in eGFR
(2) Reaching end-stage renal disease
• Sustained eGFR <15mL/min or,
• Chronic dialysis treatment or,
• Receiving a renal transplant
(3) Renal death
• To determine whether dapagliflozin, compared with placebo, reduces
the incidence of all-cause mortality.
Time to death from any cause.
Exploratory objectives
• To compare the effect of dapagliflozin vs. placebo on an expanded
composite outcome reflecting worsening of HF
Time to the first occurrence of any of the components of the
expanded composite worsening HF outcome:
(1) CV death
(2) Hospitalization for HF
(3) An urgent HF visit
(4) Documented evidence of worsening HF symptoms/signs
leading to initiation of a new treatment for HF sustained
for at least 4weeks or augmentation of existing oral therapy
for HF (e.g. increase in dose of diuretic) sustained for at
least 4weeks
• To determine whether dapagliflozin compared with placebo will have
effect on NYHA class
Change in NYHA class from baseline
• To determine whether dapagliflozin compared with placebo will
reduce the incidence of diagnosis of AF in patients without history of
AF at baseline
Proportion of patients without history of AF at baseline with a new
diagnosis of AF during the study
• To determine whether dapagliflozin compared with placebo will result
in a reduction of the incidence of hyper- and hypokalaemia
Time to the first occurrence of each of any of the following central lab
levels of serum potassium:
•> 6.0mmol/L
•> 5.5mmol/L
•< 3.5mmol/L
•< 3.0mmol/L
• To determine whether dapagliflozin compared with placebo will affect
the number of events of doubling of serum creatinine
Number of events with doubling of serum creatinine (compared with
the most recent laboratory measurement)
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Table 2 Continued
Outcome measure
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
• To determine whether dapagliflozin compared with placebo will
reduce the incidence of diagnosis of T2DM in patients without
diabetes at baseline
Proportion of patients without T2DM at baseline with a new diagnosis
of T2DM during the study
• To determine whether dapagliflozin compared with placebo will have
effect on HbA1c in the T2DM subgroup
Changes in HbA1c from baseline
• To determine whether dapagliflozin compared with placebo will have
an effect on systolic BP
Change in systolic BP from baseline
• To determine whether dapagliflozin compared with placebo will have
an effect on body weight
Change in body weight from baseline
• To determine whether dapagliflozin compared with placebo will
reduce the incidence of MI
Time to first fatal or non-fatal MI
• To determine whether dapagliflozin compared with placebo will
reduce the incidence of any stroke (ischaemic, haemorrhagic, or
undetermined)
Time to first fatal or non-fatal stroke of any cause
• To compare the effect of dapagliflozin vs. placebo on health status
assessed by PGIC and PGIS questionnaires
Changes in health status measured by PGIC and PGIS
• To compare the effect of dapagliflozin vs. placebo on health status
assessed by EQ-5D-5 L to support health economic analysis and
health technology assessment
Changes in health status measured by EQ-5D-5 L
• To collect and analyse pharmacokinetic samples for dapagliflozin
concentration
Results will be reported separately
• To assess cardiac structure and function with echocardiography at
baseline and 8-month follow-up
Results will be reported separately
• To collect and store samples of plasma and serum for future
exploratory biomarker research
Results will be reported separately
Safety objectives
• To evaluate the safety and tolerability of dapagliflozin in this patient
population
(1) Serious AEs
(2) Discontinuation of IP due to AEs
(3) Changes in clinical chemistry/haematology parameters
(4) AEs of interest [volume depletion, renal events, major
hypoglycaemic events, fractures, diabetic ketoacidosis, AEs
leading to amputation and AEs leading to a risk for lower limb
amputations (‘preceding events’)]
AE, adverse event; AF, atrial fibrillation; BP, blood pressure; CV, cardiovascular; eGFR, estimated glomerular filtration rate; EQ-5D-5 L, EuroQol five-dimensional five-level
questionnaire; HbA1c, glycated haemoglobin; HF, heart failure; IP, investigational product; KCCQ, Kansas City Cardiomyopathy Questionnaire; MI, myocardial infarction;
NYHA, New York Heart Association; PGIC, Patient Global Impression of Change; PGIS, Patient Global Impression of Severity; T2DM, type 2 diabetes mellitus.
The contribution of each component of the primary composite
endpoint to the overall treatment effect will also be examined. Total
(including recurrent) events will be analysed using a semi-parametric
proportional rates model to test the treatment effect and to quantify
the treatment difference (and other analytical methods may also be
considered).
The primary efficacy endpoint and secondary efficacy endpoints will
be examined in subgroups determined by baseline variables reflecting
demography, geographical region, heart failure characteristics, diabetes
status, kidney function, and additional co-morbidities, concomitant
medications, and others.
Full details of all analyses will be provided in a statistical analysis
plan completed before the end of the trial and unblinding of the
results. ..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.. Data Monitoring Committee and interim analysis
A DMC will oversee safety in DAPA-HF and will undertake one
planned interim efficacy analysis when 75% of the primary events
are adjudicated (the DMC can also conduct an additional interim
analysis, if deemed necessary). The significance level for final analy-
sis will be determined by the Haybittle–Peto function based on the
actual number and timing of interim analyses. The interim analysis
will use a Haybittle–Peto rule with testing of the primary compos-
ite endpoint first at a one-sided alpha level of 0.001, and then, if
superiority of dapagliflozin over placebo is achieved, testing of car-
diovascular death at a one-sided level of 0.001.18 If this is signifi-
cant, the DMC will then evaluate the totality of the efficacy data
and safety data, to determine whether the benefit is sufficiently
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unequivocal and overwhelming to recommend early termination of
the trial.
Ancillary studies
Serial echocardiography will be carried out in subset of patients,
and baseline and follow-up blood samples are being collected for future
measurement of biomarkers of interest.
Trial design and governance
DAPA-HF was designed jointly by AstraZeneca and the Executive
Committee with review, refinement and final approval of the protocol
by these parties and the country National Lead Investigators. The
conduct of the trial is overseen by AstraZeneca and the Executive
Committee working in conjunction with the National Lead Investi-
gators. Membership of all committees is listed in the supplementary
Appendix S1.
Discussion
Several aspects of the design of DAPA-HF merit discussion.
Study drug and dose
Dapagliflozin is a once daily, selective, competitive, reversible
inhibitor of SGLT2 with similar in vitro potency to canagliflozin
and empagliflozin.19–23 It causes a dose-dependent increase
in urinary glucose excretion with a near maximum effect at
10mg daily and has no clinically important drug interactions.
In common with other SGLT2 inhibitors, dapagliflozin causes
small reductions in blood pressure and weight, a small initial
increase in creatinine (although long-term treatment with SGLT2
inhibitors appears to be reno-protective in type 2 diabetes – see
below), as well as an increase in the risk of genital mycotic
infection.
Why an SGLT2 inhibitor in patients
with heart failure with reduced ejection
fraction?
As described in the introduction, canagliflozin, empagliflozin
and dapagliflozin reduced the risk of heart failure hospitaliza-
tion among patients with type 2 diabetes and cardiovascular
disease/cardiovascular risk factors, with an apparently similar
treatment effect in the small subgroup (∼10–15%) of patients
in each trial with baseline heart failure of undetermined pheno-
type, as illustrated in a meta-analysis of EMPA-REG OUTCOME,
CANVAS and DECLARE–TIMI 58.7–9,23 Examination of the
event curves in these trials shows a reduction in heart failure
hospitalization within weeks to months of randomization. The
rapidity of onset of the benefit in the three trials is not con-
sistent with traditional views about the mechanisms and time
course of cardiovascular protection accruing with conventional
glucose-lowering therapies.9–12,24–27 Consequently, numerous
additional beneficial mechanisms have been proposed, ranging ..
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.. from diuretic–haemodynamic actions, through effects on cardiac
metabolism, adipokines, myocardial fibrosis, uric acid, myocyte
ion channels and kidney function.3–12,24–28 A recent mediation
analysis suggested that the rise in haematocrit concentration
following SGLT2 inhibitor treatment is related to benefit, sup-
porting a diuretic action, and mathematical modelling suggests
SGLT2 inhibitors may remove fluid preferentially from the inter-
stitial space and cause less intravascular volume contraction.27,28
Other data suggest SGLT2 inhibition can lead to ketogene-
sis and an increase in 𝛽-hydroxybutyrate, which provides an
alternative and more efficient substrate for myocardial energy
generation.
Key inclusion and exclusion criteria
Patients with HFrEF have both a high prevalence of dysglycaemia
and high risk of adverse outcomes.1,2,13,14 Those with persisting
symptoms and elevation of natriuretic peptides despite conven-
tional therapy are in particular need of additional treatments
to reduce morbidity and mortality. The additional mechanisms
of SGLT2 inhibitor action discussed above should be beneficial
not only in patients with diabetes and pre-diabetes, but also in
the minority who are euglycaemic.9–12,24–28 Hence DAPA-HF
includes patients irrespective of diabetes status and HbA1c
concentration.
Because of the known reduction in blood pressure with
SGLT2 inhibition and similar action of conventional therapies
for HFrEF, entry systolic blood pressure must be 95mmHg or
above. Similarly, because of the small initial reduction in eGFR
expected with dapagliflozin (and similar effects from conven-
tional HFrEF therapies), as well as the diminished glycosuric
action of SGLT2 inhibitors in patients with severe renal impair-
ment, patients are only eligible for DAPA-HF if their eGFR is
≥ 30mL/min/1.73m2.
Key aspects of trial design
A visit early (14± 3 days) after randomization is included to check
renal function and blood pressure (as well as for symptoms
of hypotension); this visit also allows for adjustment of back-
ground diuretic or other non-essential therapies (as reduction
of doses of key life-saving HFrEF therapies is discouraged).
Dose reduction to 5mg of dapagliflozin or matching placebo
(or discontinuation of study drug) is permitted, as needed
at this visit or any subsequent visit; however, dose up-titration
(or re-initiation) is encouraged thereafter in all cases, where
possible.
Optional biomarker and echocardiography sub-studies are being
conducted.
Choice of endpoints
The primary outcome in DAPA-HF is the composite of car-
diovascular death, heart failure hospitalization, or an urgent
heart failure visit. The third component is an addition to the
composite most often used in recent HFrEF trials.17,29,30 Its
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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inclusion reflects two key developments. Firstly, in many parts
of the world (but particularly in the USA) considerable effort
has been made to treat heart failure outside the usual in-patient
ward setting.31 Secondly, and more importantly, there is evidence
that even exacerbations of heart failure occurring in the out-
patient setting which necessitate treatment are associated with
a poor subsequent prognosis — comparable to that of heart
failure hospitalization.32,33 Therefore, we believe that this broader
composite endpoint more completely captures prognostically
important events in the life course of patients with heart failure.
These events are rigorously defined and adjudicated, and the
components of the composite will be examined separately for
consistency of treatment effect (and the conventional two-part
composite will be the first secondary endpoint).16 Specifically, the
outpatient heart failure visits included in the primary outcome
will only be those leading to an urgent, unplanned assessment
by a physician (e.g. in an emergency department) and requir-
ing treatment for worsening heart failure (other than just an
increase in oral diuretics), in accordance with the Standardized
Definitions for Cardiovascular and Stroke Endpoint Events in
Clinical Trials.16
Two other key secondary endpoints also reflect new insights
into the experience of patients with HFrEF. We will look at
recurrent (i.e. first as well as subsequent) heart failure events,
again better reflecting the overall burden of HFrEF on patients
and health care systems.34–37 In addition, we will examine the
effect of dapagliflozin on a patient-reported outcome, i.e. the
KCCQ. Use of the KCCQ has shown that many patients with
HFrEF experience important deterioration in symptoms, function
and health-related quality of life even in the short term, without
experiencing hospital admission or death.38,39 It has proven to
be sensitive to therapeutic interventions and is prognostically
important.38–40
Given the benefits of SGLT2 inhibitors on renal function in
patients with type 2 diabetes and the prevalence and importance
of renal impairment in HFrEF, we have also included assessment
of progression of kidney disease as another pivotal secondary
endpoint.41,42
Power calculations and statistical analysis
Key questions in designing DAPA-HF were what rate might be
anticipated for the novel primary composite endpoint and what
treatment effect size is clinically relevant and realistic? The
event rate was estimated based on recent trials, particularly
PARADIGM-HF.32 A treatment effect size of 20% was cho-
sen as clearly clinically relevant and reasonably conservative in
light of the ∼30% relative risk reduction in heart failure hos-
pitalization observed in EMPA-REG OUTCOME, CANVAS and
DECLARE–TIMI 58.7–9 DAPA-HF is powered for this treatment
effect on the primary composite outcome and not the individual
components of the composite, particularly cardiovascular death.
Furthermore, for nearly all other plausible scenarios, using the
treatment effect sizes observed in DECLARE–TIMI 58 and in the
SGLT2 inhibitor trial meta-analysis, DAPA-HF has ≥ 80% power to
detect a benefit of dapagliflozin.7–9 ..
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.. Safety considerations
In view of the safety information collected in prior trials, including
DECLARE–TIMI 58, adverse event reporting has been sim-
plified (with agreement of the regulatory authorities) — only
serious adverse events, adverse event leading to treatment
discontinuation/interruption/dose reduction and adverse event
of special interest are collected. Adverse events of interest
(in light of the profile of dapagliflozin above and concerns
with SGLT2 inhibitors and other diabetes drugs more gen-
erally) include volume depletion, renal dysfunction, major
hypoglycaemic episodes, fractures, and diabetic ketoacido-
sis. There is also a regulatory requirement to document
amputations as a result of observations in the canagliflozin
development programme but not in EMPA-REG OUTCOME or
DECLARE–TIMI 58.43
Current status
The first enrolment (Visit 1) took place 8 February 2017 and the
first randomization (Visit 2) occurred 15 February 2017. Subse-
quent recruitment in DAPA-HF was rapid, and randomization was
completed 17 August 2018.
Conclusions
DAPA-HF will determine the efficacy and safety of the SGLT2
inhibitor dapagliflozin added to conventional therapy in a broad
spectrum of patients with HFrEF. A partner morbidity/mortality
trial in patients with heart failure and preserved ejection fraction
has recently commenced (DELIVER: Dapagliflozin Evaluation
to improve the LIVEs of patients with pReserved ejection frac-
tion heart failure; NCT03619213). DAPA-HF and DELIVER will
determine whether SGLT2 inhibitors are a safe and effective
treatment for patients with established and well characterised
heart failure of both major phenotypes, distinct from the trials
with these agents to date, which have largely examined the pre-
vention of heart failure. Moreover, DAPA-HF and DELIVER
will include a large proportion of patients without type 2 dia-
betes, also differing from EMPA-REG OUTCOME, CANVAS
and DECLARE–TIMI 58, which included only patients with type 2
diabetes. DAPA-HF and DELIVER are complemented by a parallel
trial in chronic kidney disease (DAPA-CKD: A Study to Evaluate
the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular
Mortality in Patients With Chronic Disease; NCT03036150).
Other trials with a different SGLT2 inhibitor, and a SGLT1/2
inhibitor, are also in progress (key features are summarised in
Table 3).
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Study plan and procedures.
Appendix S1. Supplementary details on DAPA-HF.
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